Biomarker Testing for Immunotherapy
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Category
  • Bladder Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Kidney Cancer
  • Lung Cancers
  • Melanoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer
For patients with advanced RCC, several factors are taken into consideration to help determine which systemic regimen to consider in the first-line and subsequent line therapy. It is important for clinicians to understand when to use regimens for their patient’s unique clinical situation and how to treatment for patients with metastatic RCC requiring second, third, fourth, or further lines of therapy.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Guidelines® Updates: Management of Metastatic Kidney Cancer
Despite significant improvements in response and survival with first-line therapies, progression is universal in patients with metastatic renal cell carcinoma requiring second, third, fourth, or further lines of therapy. The challenge lies in what best sequence of treatment to use that will provide maximum benefit.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Kidney Cancer, Version 2.2020
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making.
Category
  • Kidney Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Pharmacists should be aware of data on targeted therapy and immunotherapy for RCC and be able to make appropriate therapy recommendations. In addition, pharmacists play an important role in the management of toxicity of targeted therapy or immunotherapy and encouraging compliance for patients on targeted therapies for RCC.
Category
  • Kidney Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date February 12, 2020